Jun 27, 2019 SOURCE: PR NewsWire
AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director
NORTH CHICAGO, Ill., June 27, 2019 /PRNewswire/ -- AbbVie issued the following forms today.
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE
IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES,
2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING
IN CONCERT WITH THEM FOR THEMSELVES OR FOR
DISCRETIONARY CLIENTS
1.
KEY INFORMATION
Name of person
dealing (Note 1) Roxanne S. Austin
---
Company dealt in
AbbVie Inc.
---
Class of relevant Common shares, par value
security to which $0.01 per share
the
dealings being
disclosed relate
(Note 2)
---
Date of dealing
26 June 2019
---
2.
INTERESTS AND SHORT POSITIONS
(a) Interests and short
positions (following dealing)
in the class of relevant
security dealt in (Note 3)
Long Short
Number (%) Number (%)
(1) Relevant securities 52,114 Common Shares
(0.004%)
---
(2) Derivatives (other than options) N/A
---
(3) Options and agreements to N/A
purchase/sell
---
Total 52,114 Common Shares
(0.004%)
---
(b) Interests and
short positions in
relevant securities of the
company, other than the
class dealt in (Note 3) N/
A
Class of relevant security: Long Short
---
Number (%) Number (%)
(1) Relevant securities
---
(2) Derivatives (other than options)
---
(3) Options and agreements to purchase/sell
---
Total
---
3.
DEALINGS
(Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5)
---
Purchase
11500 common shares $67.50
---
(b) Derivatives transactions
(other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD
(Note 6)
(Note 7) (Note 5)
---
(c) Options transactions in
respect of existing relevant
securities
(i) Writing, selling,
purchasing or varying
Product name,
Writing, selling,
Number of securities Exercise Type, e.g. Expiry
Option money
e.g. call option purchasing, to which the option
price American,
date paid/received
varying etc. relates (Note 7) European etc. per unit (Note 5)
---
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option unit (Note 5)
---
(d) Other dealings
(including transactions in
respect of new securities) (Note
4)
Nature of transaction Details
Price per unit
(Note 8)
(if applicable) (Note 5)
---
4. OTHER INFORMATION
Agreements, arrangements or
understandings relating to options or
derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to
the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or
future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
If none, this should be stated.
---
Is a Supplemental Form 8 attached? (Note 9) YES/NOSQRT
Date of disclosure
27 June 2019
--- ---
Contact name Steven L. Scrogham
--- ---
Telephone number
847-938-6166
--- ---
Name of offeree/offeror with which
AbbVie Inc.
acting in concert
--- ---
Specify category and nature of Director of AbbVie Inc.
acting in concert status
--- ---
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE
IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES,
2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING
IN CONCERT WITH THEM FOR THEMSELVES OR FOR
DISCRETIONARY CLIENTS
1.
KEY INFORMATION
Name of person
dealing (Note 1) William J. Chase
---
Company dealt in
AbbVie Inc.
---
Class of relevant Common shares, par value
security to which $0.01 per share
the
dealings being
disclosed relate
(Note 2)
---
Date of dealing
26 June 2019
---
2.
INTERESTS AND SHORT POSITIONS
(a) Interests and short
positions (following dealing)
in the class of relevant
security dealt in (Note 3)
Long Short
Number (%) Number (%)
(1) Relevant securities 169,552 Common Shares
(0.01%)
---
(2) Derivatives (other than options) N/A
---
(3) Options and agreements to purchase/sell 641,027 Options
(0.04%)
112,376 Performance
Shares (0.01%)
under AbbVie Share
Plans
---
Total 922,955 (0.06%)
---
(b) Interests and
short positions in
relevant securities of the
company, other than the
class dealt in (Note 3) N/
A
Class of relevant security: Long Short
---
Number (%) Number (%)
(1) Relevant securities
---
(2) Derivatives (other than options)
---
(3) Options and agreements to purchase/sell
---
Total
---
3.
DEALINGS
(Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5)
---
Purchase
30400 common shares $67.30
---
(b) Derivatives transactions
(other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD
(Note 6)
(Note 7) (Note 5)
---
(c) Options transactions in
respect of existing relevant
securities
(i) Writing, selling,
purchasing or varying
Product name,
Writing, selling,
Number of securities Exercise
Type, e.g. Expiry
Option money
e.g. call option purchasing, to which the option
price American,
date paid/received
varying etc. relates (Note 7)
European etc. per unit (Note 5)
---
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option unit (Note 5)
---
(d) Other dealings
(including transactions in
respect of new securities) (Note
4)
Nature of transaction Details
Price per unit
(Note 8)
(if applicable) (Note 5)
---
4. OTHER INFORMATION
Agreements, arrangements or
understandings relating to options or
derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future
acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none,
this should be stated.
---
Is a Supplemental Form 8 attached? (Note 9) YES/NOSQRT
Date of disclosure
26 June 2019
--- ---
Contact name
Steven L. Scrogham
--- ---
Telephone number
847-938-6166
--- ---
Name of offeree/offeror with which
AbbVie Inc.
acting in concert
--- ---
Specify category and nature of Director of subsidiaries of
AbbVie Inc.
acting in concert status
--- ---
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE
IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES,
2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING
IN CONCERT WITH THEM FOR THEMSELVES OR FOR
DISCRETIONARY CLIENTS
1.
KEY INFORMATION
Name of person
dealing (Note 1)
Edward J. Rapp
---
Company dealt in
AbbVie Inc.
---
Class of relevant Common shares, par value
security to which $0.01 per share
the
dealings being
disclosed relate
(Note 2)
---
Date of dealing
26 June 2019
---
2.
INTERESTS AND SHORT POSITIONS
(a) Interests and short
positions (following dealing)
in the class of relevant
security dealt in (Note 3)
Long Short
Number (%) Number (%)
(1) Relevant securities 30,662 Common Shares
(0.002%)
---
(2) Derivatives (other than options) 14,907 stock
equivalent units
(0.001%)
---
(3) Options and agreements to purchase/sell N/A
---
Total 45,569 (0.003%)
---
(b) Interests and
short positions in
relevant securities of the
company, other than the
class dealt in (Note 3) N/
A
Class of relevant security: Long Short
---
Number (%) Number (%)
(1) Relevant securities
---
(2) Derivatives (other than options)
---
(3) Options and agreements to purchase/sell
---
Total
---
3.
DEALINGS
(Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5)
---
Purchase
7500 common shares $67.30
---
(b) Derivatives transactions
(other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD
(Note 6)
(Note 7) (Note 5)
---
(c) Options transactions in
respect of existing relevant
securities
(i) Writing, selling,
purchasing or varying
Product name,
Writing, selling,
Number of securities Exercise
Type, e.g. Expiry
Option money
e.g. call option purchasing, to which the option
price American,
date paid/received
varying etc. relates (Note 7) European etc. per unit (Note 5)
---
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option unit (Note 5)
---
(d) Other dealings
(including transactions in
respect of new securities) (Note
4)
Nature of transaction Details
Price per unit
(Note 8)
(if applicable) (Note 5)
---
4. OTHER INFORMATION
Agreements, arrangements or
understandings relating to options or
derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to
the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or
future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
If none, this should be stated.
---
Is a Supplemental Form 8 attached? (Note 9) YES/NOSQRT
Date of disclosure
27 June 2019
--- ---
Contact name Steven L. Scrogham
--- ---
Telephone number
847-938-6166
--- ---
Name of offeree/offeror with which
AbbVie Inc.
acting in concert
--- ---
Specify category and nature of Director of AbbVie Inc.
acting in concert status
--- ---
View original content:http://www.prnewswire.com/news-releases/abbvie-inc---form-8-1---statement-of-stock-purchase-by-director-300876294.html
SOURCE AbbVie
